A Phase III Study of Belatacept‐based Immunosuppression Regimens versus Cyclosporine in Renal Transplant Recipients (BENEFIT Study)
By F. Vincenti, B. Charpentier, Y. Vanrenterghem, L. Rostaing, B. Bresnahan, P. Darji, P. Massari, G. Mondragón-Ramírez, M. Agarwal, G. Russo and 3 more. American Journal of Transplantation, 2010
891 citations recorded by the source corpus.
Subfields: Epidemiology, Surgery, Transplantation
View Paper: https://www.semanticscholar.org/paper/15909bf7600653aa255e788985468a38a85f876b
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Surgery
In Transplantation
Citations in the corpus
- CD28 Negative T cells: is their loss our gain? (2014, background): “Belatacept, a fusion protein that inhibits CD28– B7 interaction, has proven to be a reasonable alternative to calcineurin inhibitor (CNI)-based therapy, but has increasingly been recognized to be ineffective in a sizable minority of kidney transplant patients (3).”
- Understanding the Causes of Kidney Transplant Failure: The Dominant Role of Antibody‐Mediated Rejection and Nonadherence (2012, background): “Early TCMR responds well to treatment (14,23,25,25,33), but may leave irreversible nephron loss, perhaps depending on the severity and time before treatment.”
- The Banff 2017 Kidney Meeting Report: Revised diagnostic criteria for chronic active T cell–mediated rejection, antibody‐mediated rejection, and prospects for integrative endpoints for next‐generation clinical trials (2018, methodology): “lead to a higher rate of graft loss in the long-term as shown by the BENEFIT-EXT study [5,6].”